Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Bristol-Myers Squibb will give Nektar Therapeutics $1.85 billion up front and potentially another $1.78 billion to jointly develop Nektar’s protein-based cancer immunotherapy NKTR-214. BMS is betting on combining NKTR-214, currently in a Phase I/II trial, with its two approved antibody checkpoint inhibitors, Opdivo and Yervoy. Trials are planned for nine tumor types. NKTR-214 is a prodrug of the immune-system-activating cytokine interleukin-2, already a cancer treatment. The drug binds the interleukin-2 receptor, leading to stimulated immune cells that target tumors.
This article has been sent to the following recipient: